A Phase Ia, Randomized, Placebo-Controlled, Single-Dose, Double-Blind, Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of SQ109 in Normal, Healthy Male and Female Volunteers
Phase of Trial: Phase I
Latest Information Update: 02 Feb 2016
At a glance
- Drugs SQ 109 (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- Sponsors Sequella
- 30 Apr 2012 New source identified and integrated (ClinicalTrials.gov record NCT01585636).
- 03 Nov 2006 New trial record.